Triapine
- Generic Name
- Triapine
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C7H9N5S
- CAS Number
- 143621-35-6
- Unique Ingredient Identifier
- U4XIL4091C
- Background
Triapine has been used in trials studying the treatment of Leukemia, Lung Cancer, Kidney Cancer, Prostate Cancer, and Pancreatic Cancer, among others.
- Associated Conditions
- -
- Associated Therapies
- -
Could Triapine With Lutetium 177 Dotatate Improve Outcomes for Neuroendocrine Tumors?
Lutetium Lu 177 dotatate shows promise for treating neuroendocrine tumors, with ongoing phase 2 trials exploring its combination with triapine to enhance efficacy. Early findings indicate safety, with efficacy data still maturing. The study aims to improve outcomes for advanced cases, exploring additional sensitizers for future research.
Targeted Oncology - Immunotherapy, Biomarkers, and Cancer
2024-2025 saw significant advancements in cancer treatment, including FDA approvals for new therapies, promising clinical trial results, and discussions on treatment strategies for various cancers. Key developments include enasidenib for IDH2-mutated AML, ropeginterferon alfa-2b for essential thrombocythemia, and new drug applications for recurrent glioma and ovarian cancer treatments.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath